Xilio Therapeutics, Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Xilio Therapeutics, Inc. has an operating margin of -955.0%, meaning the company retains $-955 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Xilio Therapeutics, Inc. has elevated debt relative to equity (D/E of 3.04), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
With a current ratio of 2.21, Xilio Therapeutics, Inc. holds $2.21 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 68/100.
While Xilio Therapeutics, Inc. generated -$18.4M in operating cash flow, capex of $36K consumed most of it, leaving -$18.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Xilio Therapeutics, Inc. passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Xilio Therapeutics, Inc. generates $0.32 in operating cash flow (-$18.4M OCF vs -$58.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Xilio Therapeutics, Inc. (XLO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Xilio Therapeutics, Inc. generated $6.3M in revenue in fiscal year 2024.
Xilio Therapeutics, Inc.'s EBITDA was -$58.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 23.7% from the prior year.
Xilio Therapeutics, Inc. generated -$18.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 73.4% from the prior year.
Xilio Therapeutics, Inc. reported -$58.2M in net income in fiscal year 2024. This represents an increase of 23.8% from the prior year.
Xilio Therapeutics, Inc. earned $-1.09 per diluted share (EPS) in fiscal year 2024. This represents an increase of 60.8% from the prior year.
Xilio Therapeutics, Inc. held $55.3M in cash against $0 in long-term debt as of fiscal year 2024.
Xilio Therapeutics, Inc. had 46M shares outstanding in fiscal year 2024. This represents an increase of 65.7% from the prior year.
Xilio Therapeutics, Inc.'s operating margin was -955.0% in fiscal year 2024, reflecting core business profitability.
Xilio Therapeutics, Inc.'s net profit margin was -918.1% in fiscal year 2024, showing the share of revenue converted to profit.
Xilio Therapeutics, Inc. invested $41.2M in research and development in fiscal year 2024. This represents a decrease of 21.0% from the prior year.
Xilio Therapeutics, Inc. invested $36K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 92.6% from the prior year.
XLO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.1M+135.8% | $8.1M+175.9% | $2.9M+29.5% | $2.3M-4.0% | $2.4M | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $14.3M-6.6% | $15.3M+85.5% | $8.3M-23.2% | $10.8M-4.1% | $11.2M+7.8% | $10.4M | N/A | $11.1M |
| SG&A Expenses | $6.7M-6.3% | $7.1M-16.4% | $8.5M+35.0% | $6.3M+8.5% | $5.8M-5.3% | $6.1M | N/A | $6.3M |
| Operating Income | -$1.9M+86.6% | -$14.4M-3.7% | -$13.9M+6.2% | -$14.8M-0.4% | -$14.7M+15.9% | -$17.5M | N/A | -$17.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$16.3M-2.8% | -$15.8M-19.4% | -$13.3M+5.4% | -$14.0M-0.7% | -$13.9M+19.1% | -$17.2M | N/A | -$16.7M |
| EPS (Diluted) | $-0.11+31.3% | $-0.16+11.1% | $-0.18+18.2% | $-0.22+8.3% | $-0.24+61.3% | $-0.62 | N/A | $-0.61 |
XLO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $133.7M-0.1% | $133.8M+29.0% | $103.7M+45.9% | $71.1M-20.9% | $89.9M+8.8% | $82.6M+35.6% | $60.9M-21.7% | $77.8M |
| Current Assets | $124.1M+0.3% | $123.7M+32.7% | $93.2M+54.7% | $60.2M-22.8% | $78.0M+12.8% | $69.2M+43.8% | $48.1M-25.4% | $64.5M |
| Cash & Equivalents | $103.8M-14.6% | $121.6M+36.5% | $89.1M+61.1% | $55.3M-26.2% | $74.9M+120.6% | $34.0M-24.0% | $44.7M-25.2% | $59.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $141.8M+11.9% | $126.7M+36.3% | $93.0M+73.9% | $53.5M-5.3% | $56.5M-0.7% | $56.8M+135.9% | $24.1M-4.9% | $25.3M |
| Current Liabilities | $56.4M+5.9% | $53.3M+11.8% | $47.6M+74.7% | $27.3M-29.5% | $38.6M+22.4% | $31.6M+97.9% | $16.0M-5.7% | $16.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$8.1M-214.5% | $7.1M-33.9% | $10.7M-39.2% | $17.6M-47.3% | $33.4M+29.7% | $25.8M-30.0% | $36.8M-29.9% | $52.5M |
| Retained Earnings | -$429.1M-3.9% | -$412.9M-4.0% | -$397.0M-3.5% | -$383.8M-7.6% | -$356.6M-4.1% | -$342.7M-5.3% | -$325.5M-5.7% | -$307.9M |
XLO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.5M-20.8% | -$14.5M-150.0% | $29.0M+304.7% | -$14.2M-171.0% | $20.0M+290.0% | -$10.5M+21.8% | -$13.4M-0.4% | -$13.4M |
| Capital Expenditures | $0-100.0% | $401K+1722.7% | $22K+266.7% | $6K | N/A | N/A | $0 | $0 |
| Free Cash Flow | -$17.5M-17.6% | -$14.9M-151.4% | $29.0M+304.4% | -$14.2M | N/A | N/A | -$13.4M-0.4% | -$13.4M |
| Investing Cash Flow | $0+100.0% | -$401K-1722.7% | -$22K-266.7% | -$6K | N/A | N/A | $0 | $0 |
| Financing Cash Flow | -$285K-100.6% | $47.4M+880.2% | $4.8M-41.1% | $8.2M-59.1% | $20.0M+2000.9% | $954K+158.4% | -$1.6M+26.9% | -$2.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
XLO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -10.1%+167.6pp | -177.7%+295.0pp | -472.7%+179.6pp | -652.3%-28.5pp | -623.8% | N/A | N/A | N/A |
| Net Margin | -85.4%+110.6pp | -196.0%+256.7pp | -452.7%+166.8pp | -619.5%-28.7pp | -590.8% | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.2%-0.3pp | -11.8%+1.0pp | -12.8%+6.0pp | -18.8%-3.3pp | -15.5%+5.3pp | -20.8% | N/A | -21.5% |
| Current Ratio | 2.20-0.1 | 2.32+0.4 | 1.96-0.3 | 2.21+0.2 | 2.02-0.2 | 2.19-0.8 | 3.02-0.8 | 3.81 |
| Debt-to-Equity | -17.52-35.4 | 17.93+9.2 | 8.69+5.7 | 3.04+1.3 | 1.69-0.5 | 2.21+1.6 | 0.65+0.2 | 0.48 |
| FCF Margin | -91.8%+92.3pp | -184.0%-1172.3pp | 988.3%+1592.8pp | -604.5% | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Xilio Therapeutics, Inc.'s annual revenue?
Xilio Therapeutics, Inc. (XLO) reported $6.3M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Xilio Therapeutics, Inc. profitable?
No, Xilio Therapeutics, Inc. (XLO) reported a net income of -$58.2M in fiscal year 2024, with a net profit margin of -918.1%.
What is Xilio Therapeutics, Inc.'s earnings per share (EPS)?
Xilio Therapeutics, Inc. (XLO) reported diluted earnings per share of $-1.09 for fiscal year 2024. This represents a 60.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Xilio Therapeutics, Inc.'s EBITDA?
Xilio Therapeutics, Inc. (XLO) had EBITDA of -$58.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Xilio Therapeutics, Inc.'s operating margin?
Xilio Therapeutics, Inc. (XLO) had an operating margin of -955.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Xilio Therapeutics, Inc.'s net profit margin?
Xilio Therapeutics, Inc. (XLO) had a net profit margin of -918.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Xilio Therapeutics, Inc.'s free cash flow?
Xilio Therapeutics, Inc. (XLO) generated -$18.4M in free cash flow during fiscal year 2024. This represents a 73.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Xilio Therapeutics, Inc.'s operating cash flow?
Xilio Therapeutics, Inc. (XLO) generated -$18.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Xilio Therapeutics, Inc.'s total assets?
Xilio Therapeutics, Inc. (XLO) had $71.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Xilio Therapeutics, Inc.'s capital expenditures?
Xilio Therapeutics, Inc. (XLO) invested $36K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Xilio Therapeutics, Inc. spend on research and development?
Xilio Therapeutics, Inc. (XLO) invested $41.2M in research and development during fiscal year 2024.
How many shares does Xilio Therapeutics, Inc. have outstanding?
Xilio Therapeutics, Inc. (XLO) had 46M shares outstanding as of fiscal year 2024.
What is Xilio Therapeutics, Inc.'s current ratio?
Xilio Therapeutics, Inc. (XLO) had a current ratio of 2.21 as of fiscal year 2024, which is generally considered healthy.
What is Xilio Therapeutics, Inc.'s debt-to-equity ratio?
Xilio Therapeutics, Inc. (XLO) had a debt-to-equity ratio of 3.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Xilio Therapeutics, Inc.'s return on assets (ROA)?
Xilio Therapeutics, Inc. (XLO) had a return on assets of -81.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Xilio Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Xilio Therapeutics, Inc. (XLO) had $55.3M in cash against an annual operating cash burn of $18.4M. This gives an estimated cash runway of approximately 36 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Xilio Therapeutics, Inc.'s Piotroski F-Score?
Xilio Therapeutics, Inc. (XLO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Xilio Therapeutics, Inc.'s earnings high quality?
Xilio Therapeutics, Inc. (XLO) has an earnings quality ratio of 0.32x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Xilio Therapeutics, Inc.?
Xilio Therapeutics, Inc. (XLO) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.